Simulations Plus (NASDAQ:SLP) Issues FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.070-1.200 for the period. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $91.8 million. Simulations Plus also updated its FY25 guidance to $1.07 to $1.20 EPS.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. BTIG Research dropped their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday. JMP Securities initiated coverage on Simulations Plus in a research note on Tuesday, July 16th. They issued a “market perform” rating on the stock. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Thursday. KeyCorp assumed coverage on shares of Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target on the stock. Finally, Craig Hallum reiterated a “buy” rating and set a $56.00 price objective on shares of Simulations Plus in a report on Wednesday, July 3rd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $54.50.

Simulations Plus Stock Down 8.9 %

Shares of SLP stock traded down $3.02 on Thursday, hitting $30.96. The stock had a trading volume of 718,228 shares, compared to its average volume of 129,364. Simulations Plus has a one year low of $29.37 and a one year high of $51.22. The business has a 50 day moving average price of $33.31 and a 200 day moving average price of $40.83. The company has a market cap of $619.51 million, a PE ratio of 64.17 and a beta of 0.69.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total transaction of $703,600.00. Following the transaction, the director now directly owns 3,501,592 shares of the company’s stock, valued at $123,186,006.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders sold 60,750 shares of company stock worth $2,145,055. 20.90% of the stock is currently owned by corporate insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.